Marion Webb has been writing about medtech since 2017, specializing in covering buzzy segments such as robotic surgery, digital therapeutics and femtech with in-depth features and interviews with leading experts. Her role includes reporting live from industry events, moderating panel discussions and podcasts, tweeting breaking news and engaging KOLs to provide high-quality, business-critical content for Medtech Insight. Marion has been writing about health care issues for more than two decades. She was a long-time biotech reporter at the San Diego Business Journal, worked at Bloomberg News, and contributed to the Los Angeles County Medical Association’s Physician Magazine. Marion was born and raised in Germany, is fluent in German and conversational in Spanish. Off the job, she’s a competitive runner, avid cyclist and swimmer, and enjoys spending time with her domestic partner and her German Shorthair Pointer mix Cora.
Latest from Marion Webb
Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.
Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.
Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.
After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.
SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.
Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.